Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study by Hurst, John R et al.
RESEARCH ARTICLE Open Access
Domiciliary pulse-oximetry at exacerbation of
chronic obstructive pulmonary disease:
prospective pilot study
John R Hurst
*, Gavin C Donaldson, Jennifer K Quint, James JP Goldring, Anant RC Patel, Jadwiga A Wedzicha
Abstract
Background: The ability to objectively differentiate exacerbations of chronic obstructive pulmonary disease (COPD)
from day-to-day symptom variations would be an important development in clinical practice and research. We
assessed the ability of domiciliary pulse oximetry to achieve this.
Methods: 40 patients with moderate-severe COPD collected daily data on changes in symptoms, heart-rate (HR),
oxygen saturation (SpO2) and peak-expiratory flow (PEF) over a total of 2705 days. 31 patients had data suitable for
baseline analysis, and 13 patients experienced an exacerbation. Data were expressed as multiples of the standard
deviation (SD) observed from each patient when stable.
Results: In stable COPD, the SD for HR, SpO2 and PEF were approximately 5 min
-1, 1% and 10l min
-1. There were
detectable changes in all three variables just prior to exacerbation onset, greatest 2-3 days following symptom
onset. A composite Oximetry Score (mean magnitude of SpO2 fall and HR rise) distinguished exacerbation onset
from symptom variation (area under receiver-operating characteristic curve, AUC = 0.832, 95%CI 0.735-0.929, p =
0.003). In the presence of symptoms, a change in Score of ≥1 (average of ≥1SD change in both HR and SpO2) was
71% sensitive and 74% specific for exacerbation onset.
Conclusion: We have defined normal variation of pulse oximetry variables in a small sample of patients with
COPD. A composite HR and SpO2 score distinguished exacerbation onset from symptom variation, potentially
facilitating prompt therapy and providing validation of such events in clinical trials.
Background
Exacerbations of chronic obstructive pulmonary disease
(COPD) are deteriorations in respiratory health that
punctuate the course of this prevalent condition [1].
Patients with COPD also experience day-to-day symp-
tom variation. Distinguishing this from exacerbation is
challenging but important as access to prompt treat-
ment at exacerbation is associated with earlier recovery
[2], while treating symptom variation as exacerbation
might result in unnecessary exposure to therapy. There
is real clinical need for an objective way to confirm
exacerbation onset, which would also be important for
validating these events in clinical trials. Current atten-
tion has focused on symptom scores to confirm
exacerbation [3], but symptoms (even when scored) are,
by definition, subjective. Despite exacerbations being
associated with increases in local and systemic inflam-
mation [4], no biomarker has been shown to reliably dif-
ferentiate stable COPD from exacerbation [5].
Exacerbations are known to be associated with
changes in physiological measures, such as peak-expira-
tory flow (PEF) [6], but absolute changes are small and
could not reliably detect exacerbations when used in
isolation [7]. We hypothesised that changes in heart rate
and oxygen saturation (SpO2), readily measurable using
pulse oximetry, might assist in the differentiation of
stable COPD from exacerbation. Despite the wide avail-
ability of such devices, and their use in tele-monitoring
programmes [8], there are no existing data examining
day-to-day variation of oximetry variables in stable
COPD, or the changes in heart rate and SpO2 observed
through the onset and recovery of exacerbations.
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pulse oximetry in a patient sample from the London
COPD cohort. Using prospective diary card data allowed
us to precisely define the onset of exacerbation symp-
toms. We have therefore been able to describe the
extent of normal variation in heart rate and SpO2 on
symptom free days, the disease and demographic char-
acteristics that affect this baseline variation, and the
time-course of changes with exacerbation. We go on to
report the ability of such data to differentiate exacerba-
tion from both stable disease and day-to-day symptom
variation.
Method
Subjects and Exacerbations
Subjects were recruited from the London COPD cohort,
first established in 1995 to investigate the causes and
mechanisms of exacerbation. The methodology has been
previously described [6]. In brief, patients attend for reg-
ular clinical assessments to comprehensively phenotype
their disease, and they complete daily diary cards. The
diary cards include assessment of PEF (best of three
attempts) and change in respiratory symptoms. Symp-
toms are only recorded when they are new or worse
than usual. The symptoms are classified as major
(breathlessness, sputum volume and sputum purulence)
and minor (cough, wheeze, sore-throat and coryza). In
this way we can monitor PEF and symptoms prior to, at
the onset of, and during exacerbations.
Exacerbations were defined using criteria that we have
previously validated against health-status [9], airway
inflammatory markers [10], lung function decline [11]
and physical activity [12]. As in these previous studies,
exacerbations were defined as two or more days of ≥2
new or worsening symptoms, at least one of which must
have been a major symptom. The first of these two days
was the day of onset. An exacerbation was considered to
have recovered on the first of two consecutive symptom
free days. This methodology also allowed us to calculate
each patient’s exacerbation frequency over the 12-
month period prior to recording pulse oximetry. The
number of major and minor symptoms recorded on
each exacerbation day was summed to give a ‘Symptom
Count’, an assessment of exacerbation severity which
can vary between zero and seven. As patients only
record symptoms when they are new or worse than nor-
mal, the Symptom Count is usually zero in stable
COPD. Days on which symptoms were recorded, but
which did not reach our criteria for exacerbation (and
were not during an exacerbation) were termed ‘symp-
tom days’, representing day-to-day symptom variation.
Days on which no additional symptoms had been
recorded, the majority, were termed ‘symptom free days’.
Patients were originally recruited from primary and
secondary care and inclusion criteria included a post-
bronchodilator Forced Expiratory Volume in 1 second
(FEV1)< 8 0 %p r e d i c t e d ,F E V 1/FVC (Forced Vital Capa-
city) ratio <0.7, minimal or no reversibility to b2-ago-
nists (<200 ml and/or 15%) and the absence of other
significant respiratory disease. At recruitment, a full
clinical assessment was performed, together with spiro-
metry (volumetric storage spirometer 122, Vitalograph
2160, Maids Moreton, Buckingham, UK). The St.
George’s Respiratory Questionnaire (SGRQ) was used to
assess health-status [13].
The study was approved by Royal Free Hampstead
NHS Trust ethics committee, and all patients provided
written informed consent.
Domiciliary Pulse Oximetry
Twenty-eight Nonin 9500 Onyx™ pulse oximeters (Ply-
mouth, Minnesota, US) were rotated through 40 patients
between September 2008 and February 2010 (a conveni-
ence sample of those attending for routine clinic appoint-
ments). The equipment complies with ISO 10993-1
(Biological Evaluation of Medical Devices) and has a manu-
facturer-stated accuracy of +/-3 min
-1 within the range 20-
250 min
-1 and +/-2% SpO2 (compared to invasive assess-
ment) within the range 70-100%. All the patients were in
sinus rhythm, none had respiratory failure, and none were
using supplementary oxygen or ventilatory support.
Patients were asked to record their daily heart rate
and SpO2 on a modified version of our standard diary
card (in addition to changes in symptoms and PEF).
Patients were given written instructions reminding them
to take the oximetry reading at the same time each
morning, before morning medication, before performing
the PEF test, from the same finger, and after sitting for
ten minutes at rest. Patients were asked to record the
highest value obtained during each measurement.
Statistical Analysis
Data were analysed using SPSS version 14.0 http://www.
spss.com. Normally distributed data are reported as
mean and standard deviation (SD), non-parametric data
as median and interquartile range (IQR). Comparisons
between groups employed t-test or ANOVA as
described in the Results. Correlations employed Pearson
and Spearman techniques.
We first assessed the extent of day-to-day variation in
heart rate, SpO2 and PEF. To do this, we calculated the
individual mean and SD of these variables in the stable
(symptom free) state. After initial distribution of the oxi-
meters to each patient, the first seven days of data were
ignored, to allow each patient to develop an oximetry
measurement routine. The mean and SD of the heart
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s y m p t o mf r e ed a y s( t h e s ed a t aw e r en o r m a l l yd i s t r i b u -
ted). For this analysis, data from seven days preceding
any exacerbation to 14 days following exacerbation
recovery were excluded. Symptom days were also
ignored. On 34 otherwise stable days (3.7%), in 30 of
the 31 patients, data were incomplete necessitating the
inclusion of additional days such that each patient had
thirty stable days monitoring of all three variables (the
final patient had a prolonged period in which oxygen
saturation was not recorded, prior to re-education). A
period of 30 days was chosen after initial inspection of
the data revealed stabilisation of the SD took up to
three weeks. This methodology implies that on subse-
quent baseline (symptom free) days, 95% of values
would be expected to lie between the mean +/- 1.96
(approximately 2) SD.
W en e x te x a m i n e dt h et i m ec o u r s eo fc h a n g e si n
heart rate, SpO2 and PEF in prospectively observed
exacerbations, in those patients with stable baseline
data. Data were examined from seven days prior, to
seven days following the onset of exacerbation symp-
toms. There were 13 exacerbations in 13 subjects for
this analysis, which is therefore based on 195 patient-
days of exacerbation monitoring.
The data in individual patients were first expressed as
multiples of that patient’s SD. This is calculated using
the formula (VD-VM)/VSD, where the measurement on
that day, stable mean and stable standard deviation of
each variable V (heart rate, oxygen saturation and PEF)
are indicated by VD,V M and VSD respectively. For
example, if a patient’sm e a n( S D )h e a r tr a t ew h e ns t a b l e
was 75 (5) min
-1, and the heart rate on the day of onset
was 85 min
-1, the value recorded would be (85-75)/5 =
+2. If the patient’s heart rate had been 70 min
-1,t h e
value recorded would be (70-75)/5 = -1.
Next, we wished to explore whether changes in oxi-
metry variables with or without PEF could reliably dis-
tinguish exacerbation onset from other days, particularly
day-to-day symptom variation (symptom days). Given
that exacerbations were typically associated with falls
(rather than rises) in SpO2 and PEF, and a rise (rather
than fall) in heart rate, we hypothesised that a compo-
site score might perform better than the individual mea-
surements alone. In preliminary analysis, we found no
evidence for a significant correlation between SpO2 and
heart rate in the stable state and therefore considered
these variables independent. There was also no signifi-
cant correlation between the greatest change in heart
rate and greatest change in oxygen saturation over the
first two exacerbation days, suggesting these variables
were indeed independent (r = -0.32, p = 0.28). We
therefore calculated an Oximetry Score (positive magni-
tude in SD units of the fall in SpO2 and rise in heart
rate, /2) and an Oximetry-PEF Score (positive magni-
tude in SD units of the fall in SpO2, fall in PEF and rise
in heart rate, /3).
We next assessed the ability of the Oximetry and Oxi-
metry-PEF scores to differentiate exacerbation onset
days from other days, in particular days on which symp-
tom variation had been recorded (symptom days). To do
this, we used all the remaining data that had not formed
part of the above analyses (see Figure 1). Days were
classified as symptom free, symptom, or exacerbation
onset as described above. At exacerbation onset, the day
with the higher score of the first two days was selected.
All other exacerbation days were ignored. This analysis
is based on 1580 days of follow-up (1469 symptom free
days, 104 symptom days, and seven exacerbation onset
days).
Receiver-operating characteristic (ROC) curves were
constructed to assess the performance of oximetry
indices and PEF in differentiating exacerbation onset
from other days, and day-to-day symptom variation
(symptom days). The test with the greatest area under
the ROC curve was taken to have the best performance.
We report sensitivity and specificity, but not positive
predictive values as these would be dependent on the
prevalence of the outcome (exacerbation) in this parti-
cular dataset.
Results
Defining Normal Variation of Pulse Oximetry variables
and PEF in Stable COPD
The study profile is illustrated as Figure 1 which shows
that of the 40 patients given oximeters, 31 had sufficient
symptom and exacerbation free data for analysis in the
stable state. Their characteristics are reported in Table
1. Their mean age was 72 years, 21 were male and their
mean FEV1 was 1.10l (45.9% predicted). The baseline
data in Table 1 were collected at routine (stable) clinic
visits closest to the start of the oximetry recording.
Of the remaining nine patients, 7/40 (17.5%) did not
have 30 days clear of all symptoms, despite prolonged
recording (median 175 days, approximately six months).
One patient received the oximeter late in January 2010,
and one patient did not record PEF correctly.
Table 1 also reports the mean of the individual patient
mean and SD for the pulse oximetry variables and PEF.
These data were normally distributed and the analysis is
based on 930 patient-days of follow-up. The mean of
the individual SD for heart rate, SpO2 and PEF, mea-
sures of day-to-day variation in the stable state, were
approximately 5 min
-1,1 %a n d1 0 lm i n
-1 respectively.
Therefore, on 95% of stable (symptom free) days
patients should have readings within approximately 10
min
-1, 2% and 20l min
-1 above and below their stable
mean value.
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tion in heart rate, SpO2, and PEF was affected by patient
or COPD characteristics. These data are reported in
Table 2. The variation in heart rate, SpO2 and PEF was
not affected by disease severity (FEV1 % predicted),
smoking status or exacerbation frequency. As expected,
older patients had reduced variation in heart rate (r =
-0.39, p = 0.030). The variation in SpO2 was statistically,
but not clinically greater in women (1.2 vs. 0.9%, p =
0.027). The mean and SD heart rate were not signifi-
cantly different between patients who were and were
not prescribed b-blocker or rate limiting calcium-chan-
nel antagonist drugs (73 vs. 79 min
-1 p=0 . 2 1 5 ,a n d4 . 8
vs. 4.9 min
-1 p = 0.883 respectively; t-test). All the
patients had already been prescribed long-acting
bronchodilators (b2-agonist and/or anti-cholinergics).
Time Course of Changes in Heart Rate, Oxygen Saturation
and PEF prior to, at onset, and with recovery of
Exacerbation
Figures 2 and 3 report the time course of the oximetry
variables and PEF, and the Symptom Count, through
the prodrome, onset and recovery with treatment of 13
exacerbations in 13 patients (12 treated, one hospita-
lised, median (IQR) delay between symptom onset and
treatment 5 (3-6) days).
T h ea v e r a g e dd a t a( w h i c hw o u l dn o tb ee x p e c t e dt o
vary significantly from zero in the baseline state) suggest
increased variation in heart rate, SpO2 and PEF immedi-
ately preceding exacerbation, a rise in heart rate, fall in
SpO2 and fall in PEF at exacerbation onset, and further
changes which are maximal at 2 days, 2 days and 3-4
days into the exacerbation respectively. The maximum
magnitude of the change in SpO2 (-1.24SD, day 2) was
smaller than the changes in heart rate (+3.09SD, day 2)
and PEF (-2.97SD, day 4).
Figures 4 and 5 report the time course of the compo-
site scores for the same exacerbations over the same
time period The scores appear to perform similarly,
b o t hs h o w i n gat e n d e n c yt or i s eo nt h ed a y sp r i o rt o
exacerbation onset, and peaking at exacerbation day two
(the third day of exacerbation symptoms). The peak
values (day two) were 2.17 (Oximetry Score) and 2.23
units (Oximetry-PEF Score).
Figure 1 Study Profile. Study profile summarising distribution of oximeters and data collection. No data were used in more than one analysis.
Hurst et al. BMC Pulmonary Medicine 2010, 10:52
http://www.biomedcentral.com/1471-2466/10/52
Page 4 of 11Ability of oximetry variables and PEF to differentiate
exacerbation onset from stable (symptom free) days and
symptom days
There were significant differences using ANOVA in the
means of both the Oximetry and the Oximetry-PEF
Scores between symptom free, symptom and exacerba-
tion onset days: Oximetry Score (0.22 vs. 0.40 vs. 1.54
respectively, p = 0.002); Oximetry-PEF Score (0.17 vs.
0.92 vs. 2.14 respectively, p < 0.001).
We calculated the area under ROC curves to inform
on the ability of the individual component variables and
two scores to confirm exacerbation onset. Table 3
reports the results in differentiation of exacerbation
onset days from any other day (symptom and symptom
free). This assesses the ability to identify exacerbation
onset in the absence of an assessment of symptoms,
providing truly objective confirmation of exacerbation.
The two composite scores performed better than the
individual variables (higher AUC), significantly better
than by chance, and both had AUC greater than the
commonly accepted criteria for validity of 0.8.
Table 4 reports the results of an analysis, illustrated in
Figure 6, assessing the ability of the components and
composite scores to differentiate exacerbation onset
days from day-to-day symptom variation (symptom
days). Notably, the mean and 95%CI values of the Oxi-
metry-PEF score were all above zero from the day of
exacerbation onset through to day seven. The Oximetry
Table 1 Clinical characteristics, and results of 30 days
stable state monitoring in 31 patients with COPD.
Mean SD
Age (years) 72.1 6.9
FEV1 (l)* 1.10 0.49
FEV1 (% predicted)* 45.9 22.7
FVC (l)* 2.46 0.82
FEV1/FVC* 0.45 0.15
Body Mass Index (BMI) (kgm
-2) 27.0 5.6
St. George’s Respiratory Questionnaire (SGRQ) (Total
Score)
49.9 16.0
Median IQR
Smoking (Pack years) 51 38-
66
Exacerbation Frequency** 3 1-4
n%
Male 21 68
Current Smokers 6 19
b-blocker or rate-limiting Calcium-channel antagonist 7 23
Mean
Stable Mean Heart Rate (min
-1) 77.8
Stable SD Heart Rate (min
-1) 4.9
Stable Mean Oxygen Saturation (SpO2) (%) 94.8
Stable SD Oxygen Saturation (SpO2) (%) 1.0
Stable Mean Peak Expiratory Flow (PEF) (lmin
1) 231.5
Stable SD Peak Expiratory Flow (PEF) (lmin
1) 11.4
*: post-bronchodilator.
**: the number of symptom-defined exacerbations over the previous year of
the study.
Table 2 Variation in, and absolute stable Heart Rate, Oxygen Saturation and peak-expiratory flow (PEF) by patient
and COPD disease characteristics; n = 31
Age
1 Sex F vs. M
2 Current Smoker vs. Not
2 FEV1 (% predicted)
1 Exacerbation Frequency
(previous yr)
3
Mean Heart Rate (min
-1) r = -0.28 80 vs. 77 77 vs. 78 r = -0.26 rho = 0.23
p = 0.134 p = 0.525 p = 0.862 p = 0.164 p = 0.207
SD Heart Rate (min
-1) r = -0.39 4.7 vs. 5.0 4.5 vs. 4.9 r = -0.35 rho = -0.05
p = 0.030* p = 0.724 p = 0.713 p = 0.054 p = 0.797
Mean Oxygen Saturation (%) r = 0.08 94 vs. 95 95 vs. 95 r = 0.14 rho = 0.21
p = 0.688 p = 0.358 p = 0.644 p = 0.470 p = 0.266
SD Oxygen Saturation (%) r = 0.17 1.2 vs. 0.9 1.0 vs. 1.0 r = -0.21 rho = -0.03
p = 0.350 p = 0.027* p = 0.769 p = 0.267 p = 0.862
Mean PEF (lmin
-1) r = -0.03 198 vs. 248 258 vs. 225 r = 0.25 rho = 0.09
p = 0.858 p = 0.085 p = 0.378 p = 0.172 p = 0.647
SD PEF (lmin
-1) r = -0.02 12 vs. 11 10 vs. 12 r = 0.10 rho = 0.00
p = 0.921 p = 0.834 p = 0.446 p = 0.608 p = 0.982
(Statistics:
1= Pearson correlation.
2= t test.
3= Spearman correlation).
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Page 5 of 11Figure 2 Time Course of Symptoms and Oximetry Variables at Exacerbation. Time course of symptom count, heart rate, oxygen saturation
(SpO2) and peak-expiratory flow (PEF) from seven days prior (-7) to exacerbation onset (day 0, vertical line) and seven days into exacerbation of
COPD. Values of the physiological variables are the mean of 13 exacerbations in 13 patients, expressed as standard deviation multiples away
from each patient’s stable mean (see text for details). A 1SD change is an approximate alteration in heart rate of 5 min
-1, SpO2 of 1% and PEF of
10l min
-1. Symptom count values are the mean from the 13 patients.
Figure 3 Time Course of Symptoms and Oximetry Variables At Exacerbation. Time course of heart rate, oxygen saturation (SpO2)a n d
peak-expiratory flow (PEF) from seven days prior (-7) to exacerbation onset (day 0, vertical line) and seven days into exacerbation of COPD. Data
expressed as mean and 95%CI (in SD units) for each variable separately.
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Page 6 of 11score performed better, but not significantly better than
the Oximetry-PEF score (AUC 0.832 vs. 0.732, p = 0.20).
The sensitivity and specificity of the Oximetry Score
in differentiating exacerbation onset from day-to-day
symptom variation is reported in Table 5. A + 1SD
change in score could represent, for example, a fall in
oxygen saturation of 1% together with a rise in heart
rate of 5 min
-1. In the presence of symptoms, such a
change had a modest sensitivity of 71% and specificity
of 74% for the presence of exacerbation. On a stable
day, the chance of a 1SD fall in SpO2 and a 1SD rise in
heart rate both occurring would be approximately 2.5%
(by definition, 68.2% of stable days lie within mean +/-
1SD for each variable, therefore on (100-68.2)/2 = 15.9%
of days this is greater than 1SD in the specified direc-
tion, and therefore the chance of both occurring
together = 0.159 × 0.159 = 2.5% days).
Discussion
We have provided a preliminary demonstration that
changes in heart rate and oxygen saturation, measured
using domiciliary pulse oximetry and incorporated into
a composite score, are able to differentiate exacerbation
onset from stable COPD with reasonable sensitivity and
specificity. In addition, we have defined the extent of
daily variation in oximetry variables in stable, ambula-
tory patients with COPD, and demonstrated changes in
these indices immediately prior to, at onset and through
the recovery of an exacerbation. Our results and metho-
dology will be of immediate interest to those employing
domiciliary oximetry tom o n i t o rC O P Da n d ,w i t h
further validation, have the potential to facilitate objec-
tive confirmation of exacerbation using simple technol-
ogy, enabling access to prompt therapy and verification
of events in clinical trials.
Our study has a number of strengths. By prospectively
recording daily symptom changes we have been able to
differentiate symptom free days from day-to-day symp-
tom variation, and by using validated criteria for exacer-
bation we have been able to differentiate symptom
variation from exacerbation onset. In total, the data
reported in this manuscript comprises 2705 days (7.4
patient-years) recording symptoms, oximetry and PEF in
31 patients with well-characterised COPD. These
patients are typical of those in whom monitoring and
early therapy at exacerbation may be desirable, having
moderate and severe disease and a previous history of
exacerbation.
Figure 4 Time Course of Oximetry and Oximetry-PEF Scores At Exacerbation. Time course of Oximetry and Oximetry-PEF scores from
seven days prior (-7) to exacerbation onset (day 0, vertical line) and seven days into exacerbation of COPD. Values are the mean score of 13
exacerbations in 13 patients (see text for details).
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natural history of COPD. Patients experiencing frequent
exacerbations have a more rapid decline in lung func-
tion [11,14], poorer quality-of-life [9], reduced physical
activity [12] and greater mortality [15]. Exacerbations
are therefore associated with a considerable burden of
health-care costs [16] such that preventing exacerbations
is a key goal of COPD therapy. Prompt therapy is asso-
ciated with more rapid exacerbation recovery [2] and
there is therefore the need to identify exacerbations
early in their course. This has resulted in attempts to
objectively confirm exacerbations, using tools such as
the EXACT-PRO [3], but quantifying symptoms does
not address the subjectivity of symptoms themselves.
Symptom scores may also be prone to ceiling effects,
and exacerbation symptoms must be differentiated from
the day-to-day symptom variations that characterise
COPD. Exacerbations remain difficult events to detect
as there is currently no diagnostic biomarker [5]. This
can result in over-treating symptom variation as exacer-
bation, and delaying exacerbation therapy when dete-
riorations are mis-attributed to symptom variation. This
may be particularly important during high-risk periods
for recurrent exacerbations, in the weeks immediately
following a first event [17]. The distinction between
stable disease and exacerbation is not just important for
patients, but is also relevant in the conduct of clinical
trials where the ability to objectively confirm these
events would be a major development.
Figure 5 Time Course of Oximetry and Oximetry-PEF Scores At Exacerbation. Time course of Oximetry and Oximetry-PEF scores from
seven days prior (-7) to exacerbation onset (day 0, vertical line) and seven days into exacerbation of COPD. Data represent the mean and 95%CI
for each score separately.
Table 3 Ability of the individual components and
composite scores to differentiate exacerbation onset
days from all other days
AUC 95%CI p =
Heart Rate 0.819 0.754-0.884 0.004
Oxygen Saturation 0.712 0.557-0.866 0.053
Peak-Expiratory Flow (PEF) 0.805 0.655-0.956 0.005
Oximetry Score 0.849 0.787-0.912 0.001
Oximetry-PEF Score 0.897 0.839-0.955 <0.001
p value represents difference from chance (AUC = 0.5).
Table 4 Ability of the individual components and
composite scores to differentiate exacerbation onset
days from symptom days (day-to-day symptom variation)
AUC 95%CI p =
Heart Rate 0.731 0.613-0.849 0.042
Oxygen Saturation 0.740 0.590-0.889 0.034
Peak-Expiratory Flow (PEF) 0.615 0.410-0.819 0.311
Oximetry Score 0.832 0.735-0.929 0.003
Oximetry-PEF Score 0.732 0.589-0.876 0.040
p value represents difference from chance (AUC = 0.5).
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and PEF immediately prior to, at onset and during
exacerbations of COPD. A composite score of change in
heart rate and SpO2 performed moderately well in dis-
tinguishing day-to-day symptom variation from COPD
exacerbation. This is a potentially important develop-
ment. Oximetry is cheap and reliable, and electronic
data capture make calculation of composite scores prac-
tical. With knowledge of a patient’s baseline heart rate
and SpO2, calculation of the score can distinguish symp-
tom variation from exacerbation onset by the second
day of symptom changes, with a cut-off that can be cho-
sen to maximise sensitivity or specificity. In this way,
inappropriate antibiotics might be avoided, and early
therapy might be facilitated. Key to our approach was
the careful collection of data from each patient at base-
line, and expression of subsequent changes as multiples
of that patient’s own, individual day-to-day variation.
Although pulse oximetry is widely used in tele-moni-
toring programs [8], and by patients themselves, we are
not aware of any previous work defining the extent of
day-to-day variation in heart rate and oxygen saturation
in patients with moderate and severe COPD. Indeed, the
European Commission Communication on Telemedicine
has highlighted the need for robust methodological stu-
dies in this area [18], such as ours. Use of oximeters
supports the current emphasis on management of long-
term conditions through self-management and care clo-
ser to (or in) the patient’s home. Even in the absence of
telemedicine, our data could be incorporated into a
written self-management plan. For example, we have
shown that there would be only a 2.5% chance of a
patient having an oxygen saturation <2% of their base-
line mean on a stable day, and a reduction in saturation
of this magnitude, or rise in heart rate >10 min
-1, might
be used to prompt re-assessment of respiratory health.
Our technique, employing simple, readily available tech-
nology is much more practical than the domiciliary
measurement of airway or systemic biomarkers which in
any case have been unable to differentiate exacerbation
from the stable state [5].
There are some limitations of our approach. We pre-
sent our findings as preliminary but believe these data
will be of immediate utility to those monitoring patients
with domiciliary oximetry, enabling subsequent valida-
tion of our technique in larger cohorts. To establish an
individual patient’s baseline, our method requires rigor-
ous data collection, at the sensitivity limit of currently
Figure 6 ROC Curves. ROC curves for the ability of the individual components, and Oximetry and Oximetry-PEF scores to differentiate
exacerbation onset from day-to-day symptom variation (symptom days) in COPD. The data are reported in Table 4.
Table 5 Sensitivity and specificity of the Oximetry Score
in differentiating exacerbation onset from symptom days
(day-to-day symptom variation) in COPD
Oximetry Score* Sensitivity Specificity
+0.5 100% 54%
+1.0 71% 74%
+1.5 29% 89%
+2.0 14% 94%
*A +1SD change in score could represent, for example, a fall in oxygen
saturation of 1% and a rise in heart rate of 5 min
-1, or no change in oxygen
saturation from baseline and a rise in heart rate of 10 min
-1. See text for
further details.
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Page 9 of 11available technology. However, with tele-health such
methods are increasingly practical. We did not include
patients with respiratory failure and it may be that oxy-
gen saturation changes at exacerbation in patients on
the steeper part of the oxygen dissociation curve are
greater. Patients in atrial fibrillation were also excluded.
We do not have data to inform on how long day-to-day
variation in the baseline state remains stable. We have
previously reported that PEF declines (slowly) with time
[11] and we are not able to state how frequently the
stable monitoring period would need to be repeated.
Our data do not inform on the ability of pulse oximetry
to distinguish exacerbation of COPD from other causes
of symptom deteriorations in these patients (such as
pneumonia), and it is quite likely that such pathologies
w o u l da l s or e s u l ti nh e a r tr a t ea n dS p O 2 changes.
Exacerbation of COPD remains a clinical diagnosis of
exclusion and the clinician (a n dp a t i e n t )m u s tr e m a i n
aware that other conditions may mimic or complicate
exacerbations [19]. We note that there were fewer unre-
ported exacerbations in this study than we have pre-
viously detected from this cohort. Finally, it is important
to remark that in some patients (17.5% in this study) it
was not possible to ascertain baseline readings on 30
symptom free days, despite prolonged monitoring, and
this might limit applicability to a proportion of patients
in clinical practice.
The Oximetry Score was able to differentiate exacer-
bation onset from day-to-day symptom variation with
reasonable sensitivity and specificity. Our data are the
first to report that day-to-day symptom variation in
COPD is associated with small, but demonstrable
changes in physiology. Addition of PEF to the oximetry
variables was not associated with a better composite
score, despite demonstrating detectable changes in PEF
at exacerbation (as previously reported [6]). This may be
because it is more difficult to assess smaller changes in
P E F ,o nas c a l ew h e r e1 0 lm i n
-1 is the minimal detect-
able difference. In addition, the PEF changes lag those
in heart rate and SpO2 and were maximal at four days
into the exacerbation (symptom day five). One attraction
of adding PEF is that this is a marker of airway involve-
m e n t ,b e l i e v e dt ob et h ep r i m a r ys i t eo fp a t h o l o g y
during exacerbations. In contrast SpO2 reflects ventila-
tion-perfusion relationships, and changes in heart rate a
variety of mechanisms including increased b2-agonist
use. We do not have data on b2-agonist use, though this
would not be expected to significantly affect changes in
oxygen saturation or PEF. Adding PEF increased the
performance of the score differentiating exacerbation
onset from all other days, regardless of symptoms, but
PEF is also effort dependent and given the difficulties in
assessing PEF reliably, and the small changes involved,
an approach restricted to heart rate and SpO2 would
seem to be more attractive. This is in contrast to the
validity of PEF during exacerbations of asthma [20].
Both scores, and individual components showed
increased variation immediately preceding exacerbation
onset, with changes that were greatest in magnitude 2-4
days following the start of exacerbation symptoms (at
about the time that patients commenced therapy). The
magnitude of the changes in heart rate and PEF were
greater than the magnitude of change in SpO2,s u c h
that many exacerbations are associated with only small
(or no) change(s) in SpO2. Much of the initial signal in
the composite scores may therefore be attributed to
alterations in heart rate. As initial changes were small, it
seems likely that exacerbation detection should remain
dependent on patients first identifying changes in symp-
toms and our data suggest that oximetry can assist in
differentiating exacerbation symptoms from day-to-day
variation. However, we have also provided evidence that
the composite scores can identify exacerbation onset
from all other days in the absence of symptom assess-
ment. The Oximetry-PEF score performed best in this
instance. Oximetry monitoring may therefore also be
important for encouraging assessment of ‘unreported’
(and therefore untreated) exacerbations [6,21], events
which contribute to the negative impact of exacerba-
tions on COPD health status.
Conclusion
In summary, this is the first report to provide data on
the day-to-day variation of heart rate and oxygen satura-
tion in ambulatory patients with stable moderate and
severe COPD. We have further described how this infor-
mation might be used to facilitate confirmation of
COPD exacerbation onset, desirable in facilitating access
to prompt treatment, and providing objective confirma-
tion of these events in the context of clinical trials.
These data will be of immediate use to those employing
domiciliary pulse oximetry monitoring in COPD, and
there is now the need to replicate these findings in sepa-
rate, larger cohorts with the aim of using oximetry to
facilitate and guide exacerbation therapy.
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